Drug intelligence / Profile preview

VTA-120

Development stage: Preclinical
Lead developer: Vita Therapeutics
Modality: Cell Therapies
Administration: Intramuscular

Overview

VTA-120 is an investigational autologous induced pluripotent stem cell (iPSC)-derived skeletal muscle satellite cell therapy being developed by Vita Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD). It is designed to combine patient-specific gene correction with iPSC technology to generate myogenic progenitor/satellite cells that can be injected intramuscularly to repair and regenerate healthy muscle tissue, addressing the underlying genetic and cellular defects driving progressive muscle weakness in FSHD.[1][4][5][6][10]

Beyond the preview

Go deeper on VTA-120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTA-120.

Explore the full profile